Zentalis Pharmaceuticals’ (ZNTL) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research note released on Friday,Benzinga reports. The brokerage currently has a $20.00 price target on the stock. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q3 2025 earnings at ($0.67) EPS and Q4 2025 earnings at ($0.68) EPS.

Other equities analysts have also issued reports about the company. Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price objective for the company in a research report on Monday, August 12th. Oppenheimer reaffirmed an “outperform” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Zentalis Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $10.00.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL stock opened at $3.47 on Friday. The stock has a market cap of $247.27 million, a PE ratio of -1.39 and a beta of 1.74. The stock has a 50-day moving average of $3.42 and a 200-day moving average of $5.38. Zentalis Pharmaceuticals has a one year low of $2.66 and a one year high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.36. As a group, research analysts anticipate that Zentalis Pharmaceuticals will post -2.76 earnings per share for the current year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Barclays PLC grew its stake in shares of Zentalis Pharmaceuticals by 18.5% in the third quarter. Barclays PLC now owns 75,395 shares of the company’s stock valued at $277,000 after buying an additional 11,748 shares in the last quarter. XTX Topco Ltd grew its stake in shares of Zentalis Pharmaceuticals by 8.7% in the third quarter. XTX Topco Ltd now owns 194,062 shares of the company’s stock valued at $714,000 after buying an additional 15,597 shares in the last quarter. Quarry LP bought a new position in shares of Zentalis Pharmaceuticals in the third quarter valued at $55,000. Paloma Partners Management Co bought a new position in shares of Zentalis Pharmaceuticals in the third quarter valued at $37,000. Finally, Erste Asset Management GmbH bought a new position in shares of Zentalis Pharmaceuticals in the third quarter valued at $37,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.